Table 2. Clinical and pathological evaluation.
| PCH group | PEH group | OR [95% CI] | P value | |
|---|---|---|---|---|
| ypT0/is,ypN0 | 1.481 (0.632-3.472) | 0.365 | ||
| No | 28 | 21 | ||
| Yes | 18 | 20 | ||
| ypT0/is,ypN0/+ | 1.645 (0.704-3.847) | 0.249 | ||
| No | 27 | 19 | ||
| Yes | 19 | 22 | ||
| MP grade for breast | NA | 0.431 | ||
| MP 5 | 19 | 22 | ||
| MP 4 | 11 | 8 | ||
| MP 3 | 5 | 6 | ||
| MP 2-0 | 11 | 5 | ||
| Clinical response after 2 cycles | 0.651(0.171-2.474) | 0.740 | ||
| CR | 2 | 3 | ||
| PR | 40 | 40 | ||
| Overall (CR or PR) | 42 | 43 | ||
| SD or PD | 6 | 4 | ||
| Clinical response after 4 cycles | 3.721(0.399-34.715) | 0.366 | ||
| CR | 7 | 11 | ||
| PR | 36 | 29 | ||
| Overall (CR or PR) | 43 | 40 | ||
| SD or PD | 4 | 1 |